British Journal of Clinical Pharmacology
Analysis of 92 studies with 107 comparisons found significant differences in the risk of ischemic stroke, thromboembolism/stroke, and intracranial haemorrhage associated with individual DOACs compared to other DOACs and Vitamin K antagonists.
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B
New England Journal of Medicine
Study (n=10) reports sustained factor IX levels in normal range with low doses of FLT180a, a liver-directed adeno-associated virus gene therapy in 9 patients with haemophilia B (median follow 27.2 months) but immunosuppression with glucocorticoids with/without tacrolimus needed.
The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services
